Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma

•Neuroendocrine carcinoma of the cervix is a rare and aggressive HPV-mediated malignancy with a high recurrence rate.•Combination ipilimumab and nivolumab has been shown to effect disease response in pulmonary neuroendocrine carcinoma.•We present three patients with recurrent neuroendocrine cervical carcinoma who experienced response to ipilimumab/nivolumab.